Announcements Trials

Browse Landscape

Status

Recruiting 171 Active not recruiting 82 Completed 72 Not yet recruiting 41 Terminated 21 Suspended 8 Withdrawn 4 Enrolling by invitation 3 Unknown 1 No longer available 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Melanoma 3 Lung Neoplasms 3 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neuroblastoma 2 Neoplasms 2 Multiple Myeloma 2 Glioblastoma 2 Wilms Tumor 1 Uterine Neoplasms 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Retinoblastoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pinealoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive 1 Neoplasms by Site 1 Meningeal Neoplasms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Glioma × 1 year × Clear all

NCT06743100 2026-05-29

18F-Floretyrosine Expanded Access Program

Telix Pharmaceuticals (Innovations) Pty Limited

No longer available

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡